The hip joint mobilization with movement technique improves muscle activity, postural stability, functional and dynamic balance in hemiplegia secondary to chronic stroke: a blinded randomized controlled trial

Arabzadeh, Soudeh; Kamali, Fahimeh; Bervis, Soha; Razeghi, Mohsen

doi:10.1186/s12883-023-03315-2

Table 4 Results of muscle activation during dynamic test within time in each group and between groups

From: The hip joint mobilization with movement technique improves muscle activity, postural stability, functional and dynamic balance in hemiplegia secondary to chronic stroke: a blinded randomized controlled trial

Parameters			Experimental (n = 10)		Control (n = 10)
Parameters			Mean change score (SD)	p value ^a	Mean change score (SD)	p value ^a	p value between groups ^b
Pre-Post test	BF	A	0.43 ± 0.08 0.35 ± 0.07	0.002* 0.003*	0.25 ± 0.35 -0.06 ± 0.17	> 0.99 > 0.99	0.007**
	BF	L	0.43 ± 0.08 0.35 ± 0.07	0.002* 0.003*	0.25 ± 0.35 -0.06 ± 0.17	> 0.99 > 0.99	0.004**
	MG	A	0.01 ± 0.09 -0.07 ± 0.11	0.98 0.96	0.11 ± 0.19 0.59 ± 0.74	0.98 0.94	0.94
	MG	L	0.01 ± 0.09 -0.07 ± 0.11	0.98 0.96	0.11 ± 0.19 0.59 ± 0.74	0.98 0.94	0.29
	RF	A	-0.67 ± 0.09 -0.40 ± 0.09	< 0.001* 0.007*	-0.14 ± 0.14 -0.34 ± 0.18	> 0.99 0.31	0.07
	RF	L	-0.67 ± 0.09 -0.40 ± 0.09	< 0.001* 0.007*	-0.14 ± 0.14 -0.34 ± 0.18	> 0.99 0.31	0.65
	TA	A	-1.27 ± 0.18 -0.46 ± 0.10	< 0.001* 0.006*	-1.07 ± 0.68 -0.10 ± 0.22	0.50 > 0.99	0.15
	TA	L	-1.27 ± 0.18 -0.46 ± 0.10	< 0.001* 0.006*	-1.07 ± 0.68 -0.10 ± 0.22	0.50 > 0.99	0.19
	RA	A	0.25 ± 0.10 1.05 ± 0.65	0.12 0.43	0.23 ± 0.27 0.25 ± 0.20	> 0.99 0.78	0.36
	RA	L	0.25 ± 0.10 1.05 ± 0.65	0.12 0.43	0.23 ± 0.27 0.25 ± 0.20	> 0.99 0.78	0.65
	ES	A	-0.28 ± 0.07 -0.04 ± 0.08	0.01* 0.08	0.05 ± 0.03 -0.009 ± 0.07	0.44 > 0.99	0.007**
	ES	L	-0.28 ± 0.07 -0.04 ± 0.08	0.01* 0.08	0.05 ± 0.03 -0.009 ± 0.07	0.44 > 0.99	0.94
Pre-Follow test	BF	A	0.34 ± 0.08 0.31 ± 0.09	0.008* 0.03*	0.44 ± 0.35 0.10 ± 0.25	0.75 > 0.99	0.06
	BF	L	0.34 ± 0.08 0.31 ± 0.09	0.008* 0.03*	0.44 ± 0.35 0.10 ± 0.25	0.75 > 0.99	0.03**
	MG	A	0.002 ± 0.07 0.08 ± 0.15	0.94 0.98	0.17 ± 0.16 0.69 ± 0.72	0.93 0.98	0.15
	MG	L	0.002 ± 0.07 0.08 ± 0.15	0.94 0.98	0.17 ± 0.16 0.69 ± 0.72	0.93 0.98	0.36
	RF	A	-0.65 ± 0.10 -0.51 ± 0.09	< 0.001* 0.003*	0.007 ± 0.07 -0.47 ± 0.31	> 0.99 0.53	0.12
	RF	L	-0.65 ± 0.10 -0.51 ± 0.09	< 0.001* 0.003*	0.007 ± 0.07 -0.47 ± 0.31	> 0.99 0.53	0.63
	TA	A	-0.87 ± 0.14 -0.80 ± 0.27	0.001* 0.05	-0.75 ± 0.59 0.16 ± 0.12	0.75 0.62	0.95
	TA	L	-0.87 ± 0.14 -0.80 ± 0.27	0.001* 0.05	-0.75 ± 0.59 0.16 ± 0.12	0.75 0.62	0.10
	RA	A	0.22 ± 0.21 1.04 ± 0.75	> 0.99 0.61	0.22 ± 0.27 0.25 ± 0.20	0.95 0.77	0.87
	RA	L	0.22 ± 0.21 1.04 ± 0.75	> 0.99 0.61	0.22 ± 0.27 0.25 ± 0.20	0.95 0.77	0.63
	ES	A	-0.31 ± 0.08 -0.07 ± 0.07	0.01* > 0.99	0.02 ± 0.03 0.01 ± 0.06	> 0.99 > 0.99	0.004**
	ES	L	-0.31 ± 0.08 -0.07 ± 0.07	0.01* > 0.99	0.02 ± 0.03 0.01 ± 0.06	> 0.99 > 0.99	0.12

Values are expressed as Mean (SD) of difference between two evaluation times. The minus sign next to the mean values means increase in onset time
Abbreviation: BF, biceps femoris; MG, medial gastrocnemius; RF, rectus femoris; TA, tibialis anterior; RA, rectus femoris; ES, erector spine; A, Affected side; L, Less affected side; SD, Standard deviation
*Significance p < 0.05, a: Repeated measure ANOVA with Bonferroni post hoc (within group)
**Significance p < 0.05, b: Mann-Whitney U-test (between groups)

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Neurology

Contact us